Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Nvidia Corp (NVDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Nvidia Corp — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Nvidia Corp trades at $217.42 (market cap $5.52T). The key difference: Nvidia Corp is far larger — about 1930.1× Dyne Therapeutics Inc. Common Stock's market cap, and Nvidia Corp pays a 0.44% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Nvidia Corp for 116 Days on average.
| DYN | NVDA | |
|---|---|---|
Market Cap | $2.86B | $5.52T |
Volume | 3,341,579 | 84,036,941 |
Sector | Health | Technology |
52-Week High | $26.78 | $239.27 |
52-Week Low | $14.60 | $165.17 |
Typical Hold Time | 0 Days | 116 Days |
Enterprise Value | $2.18B | $5.49T |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
NVIDIA (NVDA) trades at $221.51, down 2.13% today, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $221. Fundamentally, the company reported stellar revenue growth to $130.50 billion in 2025 and a net income margin of 63.66%, though valuation ratios like a P/E of 28.89 and P/S of 18.4 remain elevated. Recent news highlights AI-driven growth potential but also concerns over market saturation.
Outlook: Strong AI demand and earnings beats support long-term growth, but high valuations and competitive pressures pose risks. Analyst consensus is bullish with a $339.17 price target, suggesting significant upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →
